Clinical trials during the COVID-19 pandemic: A global guide

The consequences of the COVID-19 pandemic continue to develop dynamically. Some countries are beginning to ease lockdown measures, whilst others retain or even impose new restrictions. The situation continues to impact the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address even more challenges to ensure the continuity of trials on human medicines.

In this updated edition, composed by our global Life Sciences sector team, we cover regulatory developments in more than 50 countries with new additions in Africa and Asia Pacific regions. The guide continues to answer questions pertaining to:

• Closing and opening of new trial sites.
• Patient transfer to other sites and managing diagnostic tests.
• Investigational visits management.
• Supply of IMPs.
• Monitoring clinical trials and subjects' data.
• Communicating with competent authorities.
• Considering initiation, continuation, stop, suspension or extension of trials.

Given the dynamically developing situation, please watch this space and our Life Sciences sector LinkedIn.

Read the full report here